Neogen chemicals Limited has announced that its board of directors will convene on February 11, 2026, to deliberate on crucial financial matters including quarterly results and fund raising initiatives. The meeting has been scheduled in compliance with SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

Financial Results Review

The board will consider, approve and take on record the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. This represents the company's Q3FY26 performance, which will provide insights into the chemical manufacturer's operational and financial performance during the period.

Fund Raising Proposal

A significant agenda item involves the evaluation and approval of fund raising proposals through multiple instruments. The company is considering various options for capital mobilization:

The fund raising initiative will be executed in accordance with the Companies Act 2013 and SEBI (Issue of Capital and Disclosure Requirement) Regulations, 2018. The board retains absolute discretion in determining the manner, terms and conditions for the capital raising exercise.

Regulatory Compliance

Neogen Chemicals has implemented a trading window closure period that commenced on January 1, 2026, following their December 27, 2025 intimation. This closure aligns with SEBI (Prohibition of Insider Trading) Regulations, 2015 and the company's internal code for prevention of insider trading.

Corporate Communication

The board meeting intimation has been formally communicated to both BSE Limited and National Stock Exchange of India Limited. Company Secretary and Compliance Officer Unnati Kanani has signed the official communication, ensuring proper regulatory disclosure. The announcement is also available on the company's website under financial performance and announcements sections, maintaining transparency with stakeholders and investors.

Neogen Chemicals Limited has disclosed a major promoter share transfer involving 57,78,500 equity shares under SEBI's Takeover Regulations. Haridas Thakarshi Kanani, Chairman Emeritus and promoter, executed the transaction through inter-se transfer arrangements to restructure promoter holdings within the specialty chemicals company.

Transaction Details

Kanani transferred 57,78,500 equity shares on December 31, 2025, representing 21.90% of the company's paid-up capital. The shares were distributed between two family trusts through off-market gift transfers with no monetary consideration involved.

Shareholding Restructuring

The transfer resulted in substantial changes to the promoter's direct shareholding pattern while maintaining overall promoter group holdings at 23.33%.

SEBI Regulatory Compliance

The transaction was conducted under Regulation 29(2) of SEBI Substantial Acquisition of Shares and Takeovers Regulations, 2011. Both family trusts obtained SEBI exemption order number WTM/KCV/CFD/17/2025-26 dated December 30, 2025, under Regulation 11(5) of SAST Regulations.

Haridas Kanani Family Trust filed detailed regulatory disclosures with BSE Limited and National Stock Exchange of India Limited on January 1, 2026. The filing confirmed the acquisition of 52,76,500 equity shares representing 20.00% of the company's paid-up capital through gift transaction from the promoter.

Corporate Structure Impact

Key compliance aspects included proper regulatory disclosures to both stock exchanges, with the company's paid-up capital remaining at ₹26,38,16,740 comprising 2,63,81,674 equity shares of ₹10 face value each. The Haridas Kanani Family Trust was classified as a promoter shareholder while H T Kanani Family Trust was designated as a promoter group shareholder post-acquisition.

The transaction maintains the aggregate promoter and promoter group holding at the same level, representing a strategic restructuring of family holdings rather than any change in overall promoter control of the specialty chemicals manufacturer. Dr. Harin Kanani signed the regulatory filings as Managing Trustee on behalf of Haridas Kanani Family Trust.